Department of Pharmacology, Institute of Biological Sciences, Pampulha, Belo Horizonte, MG, Brazil.
Nitric Oxide. 2012 Mar 31;26(3):157-61. doi: 10.1016/j.niox.2012.01.006. Epub 2012 Feb 4.
Despite the classical peripheral pronociceptive effect of noradrenaline (NA), recently studies showed the involvement of NA in antinociceptive effect under immune system interaction. In addition, the participation of the NO/cGMP/KATP pathway in the peripheral antinociception has been established by our group as the molecular mechanism of another adrenoceptor agonist xylazine. Thus the aim of this study was to obtain pharmacological evidences for the involvement of the NO/cGMP/KATP pathway in the peripheral antinociceptive effect induced by exogenous noradrenaline. The rat paw pressure test was used, with hyperalgesia induced by intraplantar injection of prostaglandin E(2) (2μg/paw). All drugs were locally administered into the right hind paw of male Wistar rats. NA (5, 20 and 80ng/paw) elicited a local inhibition of hyperalgesia. The non-selective NO synthase inhibitor l-NOarg (12, 18 and 24μg/paw) antagonized the antinociception effect induced by the highest dose of NA. The soluble guanylyl cyclase inhibitor ODQ (25, 50 and 100μg/paw) antagonized the NA-induced effect; and cGMP-phosphodiesterase inhibitor zaprinast (50μg/paw) potentiated the antinociceptive effect of NA low dose (5ng/paw). In addition, the local effect of NA was antagonized by a selective blocker of an ATP-sensitive K(+) channel, glibenclamide (20, 40 and 80μg/paw). On the other hand, the specifically voltage-dependent K(+) channel blocker, tetraethylammonium (30μg/paw), Ca(2+)-activated K(+) channel blockers of small and large conductance types dequalinium (50μg/paw) and paxilline (20μg/paw), respectively, were not able to block local antinociceptive effect of NA. The results provide evidences that NA probably induces peripheral antinociceptive effects by activation of the NO/cGMP/KATP pathway.
尽管去甲肾上腺素(NA)具有经典的外周敏化作用,但最近的研究表明,在免疫系统相互作用下,NA 参与了镇痛作用。此外,我们小组已经确定,NO/cGMP/KATP 通路的参与是另一种肾上腺素受体激动剂二甲噻嗪产生外周镇痛的分子机制。因此,本研究旨在获得药理学证据,证明外源性去甲肾上腺素诱导的外周镇痛作用涉及 NO/cGMP/KATP 通路。使用足底注射前列腺素 E2(2μg/爪)诱导的痛觉过敏来检测大鼠爪压力试验。所有药物均局部给药于雄性 Wistar 大鼠的右后爪。NA(5、20 和 80ng/爪)局部抑制痛觉过敏。非选择性一氧化氮合酶抑制剂 l-NOarg(12、18 和 24μg/爪)拮抗 NA 最高剂量诱导的镇痛作用。可溶性鸟苷酸环化酶抑制剂 ODQ(25、50 和 100μg/爪)拮抗 NA 诱导的作用;cGMP 磷酸二酯酶抑制剂扎普司特(50μg/爪)增强了 NA 低剂量(5ng/爪)的镇痛作用。此外,ATP 敏感性 K+通道的选择性阻断剂格列本脲(20、40 和 80μg/爪)拮抗了 NA 的局部作用。另一方面,电压依赖性 K+通道的特异性阻断剂四乙铵(30μg/爪)、小电导型和大电导型钙激活型 K+通道的阻断剂分别为地喹氯铵(50μg/爪)和帕西利嗪(20μg/爪),无法阻断 NA 的局部镇痛作用。结果表明,NA 可能通过激活 NO/cGMP/KATP 通路诱导外周镇痛作用。